Ian Bedford
Geen lopende functies
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Ian Mark Buckley-Golder | M | 72 |
Xceleron Ltd.
 Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
| Susan Proctor | F | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 7 jaar |
| John W. Holaday | M | 78 |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
| Frank Armstrong | M | 67 |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
| Edward William Anthony Lascelles | M | 49 |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
| Michael John Butler | M | 64 |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 5 jaar |
| Iyad Omari | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | - |
| Colin Garner | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 17 jaar |
| June Garner | F | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 16 jaar |
| Jeremy Hague | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 10 jaar |
| Graham Lappin | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 12 jaar |
| Mark Seymour | M | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 6 jaar |
| June McLenaghan | F | - |
Xceleron Ltd.
Xceleron Ltd. Miscellaneous Commercial ServicesCommercial Services Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom. | 10 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigd Koninkrijk | 13 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Ian Bedford
- Persoonlijk netwerk
